The Recall Desk

Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Filters

Agency

Category

Minimum severity

Clear filters

5951–5975 of 11856

  • SevereFDA (Drugs)·D-1154-2018·2018-09-05

    Pharmcore Recalls Methylcobalamin Vials Due to Sterility Concerns

    Pharmcore Inc. is recalling 1,115 vials of Methylcobalamin 10 mg due to a lack of assurance of sterility. The product was distributed nationwide.

    Product
    Methylcobalamin 10 mg vial Lyophilized 1109 East Hallandale Beach Blvd. Hallandale Beach, FL 33009
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1164-2018·2018-09-05

    Auro Pharmacies Recalls Testosterone Cypionate/Enanthate Injectable Due to Sterility Concerns

    Auro Pharmacies is recalling 32 vials of Testosterone Cypionate/Enanthate injectable because inadequate processes and equipment failed to assure the sterility of the product.

    Product
    Testosterone Cypionate/Enanthate injectable, 200/50 mg/mL, packaged in a) 5 mL and 8 mL Multiple Dose vials, Rx only, Central Drugs Compounding Pharmacy, 520 W. La Habra Blvd, La Habra, CA 90631
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1156-2018·2018-09-05

    Auro Pharmacies Recalls CoEnzyme-Q10 Injectable Due to Sterility Concerns

    Auro Pharmacies is recalling 39 vials of CoEnzyme-Q10 injectable because inadequate processes and equipment failed to assure product sterility.

    Product
    CoEnzyme-Q10 injectable, 20 mg/mL, 10 mL Multiple Dose vial, Rx only, Central Drugs Compounding Pharmacy, 520 W. La Habra Blvd, La Habra, CA 90631
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1163-2018·2018-09-05

    Auro Pharmacies Recalls Testosterone Injectable Due to Sterility Concerns

    Auro Pharmacies is recalling 43 vials of Testosterone Cypionate/Enanthate injectable because inadequate processes and equipment failed to assure product sterility.

    Product
    Testosterone Cypionate/Enanthate injectable, 126/54 mg/mL, packaged in a) 3 mL and b) 5 mL Multiple Dose vials, Rx only, Central Drugs Compounding Pharmacy, 520 W. La Habra Blvd, La Habra, CA 90631
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1139-2018·2018-09-05

    Torrent Pharma Recalls Amlodipine and Valsartan Tablets Due to Impurity

    Torrent Pharma Inc. is recalling Amlodipine and Valsartan Tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Amlodipine and Valsartan Tablets, USP, 10 mg/160mg, 30 tablets per bottle, Rx Only, Manufactured by: Torrent Pharmaceuticals LTD., Indrad-382 721, India. NDC: 13668-206-30
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1167-2018·2018-09-05

    Auro Pharmacies Recalls Methyl-Cobalamin Injectable Due to Sterility Concerns

    Auro Pharmacies is recalling 74 vials of Methyl-Cobalamin injectable because the manufacturer could not assure the sterility of the product.

    Product
    Methyl-Cobalamin injectable, 2 mg/mL, 30 ml Multiple Dose vial, Rx only, Central Drugs Compounding Pharmacy, 520 W. La Habra Blvd, La Habra, CA 90631
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-1128-2018·2018-09-05

    Baxter Recalls 0.9% Sodium Chloride Injection Due to CGMP Deviations

    Baxter Healthcare is recalling 33,600 bags of 0.9% Sodium Chloride Injection USP due to Current Good Manufacturing Practice (CGMP) deviations. The product was distributed only in Texas and Mississippi.

    Product
    SODIUM CHLORIDE — SODIUM CHLORIDE (SODIUM CHLORIDE)
    Category
    Drug
    Distribution
    2 states
  • CriticalFDA (Drugs)·D-1182-2018·2018-08-29

    FDA Recalls Levothyroxine and Liothyronine Thyroid Tablets Due to Content Uniformity Failures

    Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications, potentially resulting in incorrect drug strength.

    Product
    Levothyroxine and Liothyronine (Thyroid Tablets, USP), 2 grain (120 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-158-04.
    Category
    Drug
    Distribution
    Distributed nationwide
  • CriticalFDA (Drugs)·D-1179-2018·2018-08-29

    FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures

    Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.

    Product
    Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1 & 1/2 grain (90 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-157-04.
    Category
    Drug
    Distribution
    Distributed nationwide
  • CriticalFDA (Drugs)·D-1178-2018·2018-08-29

    FDA Recalls Levothyroxine and Liothyronine Thyroid Tablets Due to Content Uniformity Failures

    Westminster Pharmaceuticals is recalling specific lots of Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient.

    Product
    Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1 grain (60 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-156-04.
    Category
    Drug
    Distribution
    Distributed nationwide
  • CriticalFDA (Drugs)·D-1180-2018·2018-08-29

    FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures

    Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.

    Product
    Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/2 grain (30 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-155-04.
    Category
    Drug
    Distribution
    Distributed nationwide
  • CriticalFDA (Drugs)·D-1181-2018·2018-08-29

    FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures

    Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.

    Product
    Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/4 grain (15 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-159-04.
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1107-2018·2018-08-29

    Preferred Pharmaceuticals Recalls Valsartan Tablets Due to Carcinogen Impurity

    Preferred Pharmaceuticals is recalling Valsartan Tablets USP 320 mg because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan Tablets USP 320 mg, 90-count, plastic child resistant bottle, Rx Only, Preferred Pharmaceuticals, Inc., 1250 N. Lakeview Ave., Suite O, Anaheim, CA 92807, NDC 68788-6882-9
    Category
    Drug
    Distribution
    1 state
  • SevereFDA (Drugs)·D-1115-2018·2018-08-29

    Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity

    Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    VALSARTAN — VALSARTAN (VALSARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1110-2018·2018-08-29

    A-S Medication Solutions Recalls Valsartan and Hydrochlorothiazide Tablets

    A-S Medication Solutions LLC is recalling Valsartan and Hydrochlorothiazide Tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan and Hydrochlorothiazide Tablets, Valsartan 160 MG and Hydrochlorothiazide 12.5 MG, 90 tablets per bottle, Rx Only, MFG: Arrow Pharm (Malta) LTD, Birzebbugia, BBG 3000 Malta. NDC: 54569-6480-0
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1116-2018·2018-08-29

    Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity

    Hetero Labs is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    VALSARTAN — VALSARTAN (VALSARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1113-2018·2018-08-29

    Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity

    Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    VALSARTAN — VALSARTAN (VALSARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1114-2018·2018-08-29

    Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity

    Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    VALSARTAN — VALSARTAN (VALSARTAN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1108-2018·2018-08-29

    A-S Medication Solutions Recalls Valsartan Tablets Due to Carcinogen Impurity

    A-S Medication Solutions LLC is recalling Valsartan Tablets 160 MG because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan Tablets, 160 MG, 30-count bottle (NDC 54569-6583-0), 90-count bottle (NDC 54569-6583-1), Rx Only, MFG: Zhejiang Huahai Pharma, Linhai, Zhejiang 317024 China
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1111-2018·2018-08-29

    A-S Medication Solutions Recalls Valsartan and Hydrochlorothiazide Tablets

    A-S Medication Solutions LLC is recalling 531 bottles of Valsartan and Hydrochlorothiazide Tablets due to the detection of a carcinogen impurity in the active pharmaceutical ingredient.

    Product
    Valsartan and Hydrochlorothiazide Tablets, Valsartan 320 MG and Hydrochlorothiazide 25 MG, 90 tablets per bottle, Rx Only, MFG: Arrow Pharm (Malta) LTD, Birzebbugia, BBG 3000 Malta. NDC: 54569-6488-0
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1109-2018·2018-08-29

    A-S Medication Solutions Recalls Valsartan Tablets Due to Carcinogen Impurity

    A-S Medication Solutions LLC is recalling 178 bottles of Valsartan Tablets, 80 MG, because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan Tablets, 80 MG, 30-count bottle (NDC 54569-6582-0, 90-count bottle (NDC 54569-6582-1), Rx Only, MFG: Zhejiang Huahai Pharma, Linhai, Zhejiang 317024 China
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-1095-2018·2018-08-22

    Northwind Pharmaceuticals Recalls Valsartan Tablets Due to Carcinogen Impurity

    Northwind Pharmaceuticals is recalling specific lots of Valsartan 160 mg tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan, 160 mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-460-52
    Category
    Drug
    Distribution
    1 state
  • SevereFDA (Drugs)·D-1097-2018·2018-08-22

    Northwind Pharmaceuticals Recalls Valsartan 80mg Due to Carcinogen Impurity

    Northwind Pharmaceuticals is recalling Valsartan 80mg tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan, 80mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-0652-52
    Category
    Drug
    Distribution
    1 state
  • SevereFDA (Drugs)·D-1096-2018·2018-08-22

    Northwind Recalls Valsartan HCTZ Tablets Due to Carcinogen Impurity

    Northwind Pharmaceuticals is recalling 43 bottles of Valsartan HCTZ 160/12.5mg tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.

    Product
    Valsartan HCTZ, 160/12.5mg, 30 tablets per bottle, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46256. NDC: 51655-950-52
    Category
    Drug
    Distribution
    1 state